🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Spatial Navigation for the Early Detection of Alzheimer's Disease.

RecruitingNAAges 50 Years - 80 YearsAllUniversity Hospital, Ghent
NCT06385951 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Alzheimer's Disease (AD) is the most common form of dementia and may contribute to 60-70 % of all cases. An early, accurate diagnosis of AD will become increasingly important with disease-modifying therapies. Different types of fluid and neuroimaging biomarkers are available for the early detection of AD. However, implementation of routine use of these biomarkers in clinical settings is held back due to the risk of overdiagnosis, increased cost and invasiveness of the assessment method. Therefore, novel biomarkers are needed beyond the amyloid and tau pathologies for the early diagnosis of AD. Neuropsychological paper and pencil tests can detect AD and discriminate between different clinical stages. Since medial temporal lobe structures, including the hippocampus and entorhinal cortex (EC), are involved in spatial navigation and degenerate in the earliest stages of AD, spatial navigation

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patients with a Mild Cognitive Impairment (MCI) due to Alzheimer's Disease (AD) * Patients with a mild Alzheimer's Dementia * Patients with MCI without a formal dementia diagnosis * Healthy controls Exclusion Criteria: * Diabetes (only for healthy controls) * Epilepsy * Presence of extreme depressive symptoms (\>11 on Geriatric depression scale or \>20 on Beck depression inventory) * Presence of extreme anxiety (\>22 on Beck Anxiety Inventory) * A major psychiatric of medical disorder * Alcohol excess * Moderate to severe white matter lesions on MRI (\>2 Fazekas) * Any visual of mobility impairment of such severity as to compromise the ability to undertake the iVR task.
💊

What it tests

  • Procedure for patients
  • Procedure for healthy controls
📍

Where

1 site
University Hospital Gent
Ghent, Belgium
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy